Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 15/20 | 0.69 |
| ▸ | HTR6 | P50406 | 14/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.66 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.66 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.66 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.66 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.66 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.66 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.66 |
| ▸ | BCHE | P06276 | 2/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | HTR2C | P28335 | 3/20 | 0.58 |
| ▸ | HTR7 | P34969 | 3/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | HRH2 | P25021 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14728770 | 0.93 | HRH1 (0.59) | HRH1HTR6GRIN1GRIN2AGRIN2B | |
| SCHEMBL3236375 | 0.93 | HRH1 (0.58) | HRH1HTR6GRIN1GRIN2AGRIN2B | |
| SCHEMBL12820252 | 0.92 | HRH1 (0.57) | HRH1HTR6GRIN1GRIN2AGRIN2B | |
| SCHEMBL2174231 | 0.91 | GRIN1 (0.71) | HRH1HTR6GRIN1GRIN2AGRIN2B | |
| SCHEMBL169856 | 0.90 | HRH1 (0.55) | HRH1HTR6GRIN1GRIN2AGRIN2B | |
| SCHEMBL13834262 | 0.90 | HRH1 (0.55) | HRH1HTR6GRIN1GRIN2AGRIN2B | |
| SCHEMBL13835017 | 0.90 | HRH1 (0.55) | HRH1HTR6GRIN1GRIN2AGRIN2B | |
| SCHEMBL176200 | 0.89 | HRH1 (0.69) | HRH1HTR6GRIN1GRIN2AGRIN2B | |
| SCHEMBL3032023 | 0.89 | GRIN1 (0.75) | HRH1HTR6GRIN1GRIN2AGRIN2B | |
| SCHEMBL12480226 | 0.89 | HTR6 (0.57) | HRH1HTR6GRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190328-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | claimed |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-05-31 | — | — | US | claimed |
| CN-102480955-A | Pyrido [4,3-b ] indoles and methods of use | MEDIVATION TECHNOLOGIES INC | 2012-05-30 | — | — | CN | claimed |
| EP-2424364-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010127177-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-11-04 | — | — | WO | claimed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550782-B2 | Compounds and methods for treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527854-B2 | Compounds and methods for treatment of hypertension | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9458155-B2 | Pyrido[4,3-b]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2012-05-31 | — | — | US | disclosed |
| WO-2010127177-A1 | PYRIDO [4,3-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2010051501-A1 | PYRIDO (4,3-B) INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190328-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | HRH1 41/4885HTR6 10/4885GRIN1 86/4885 |
| US-20120136008-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | HRH1 41/4885HTR6 10/4885GRIN1 86/4885 |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | HRH1 537/4885HTR6 13/4885GRIN1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.